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Multiple sclerosis is an autoimmune inflammatory disorder of
the central nervous system. The global prevalence of the
condition varies widely, with the most recent meta-analysis
finding an increase in 3 cases per 100 000 per degree of latitude.1
The disease is more common in females, with a female to male
incident ratio of 2.4.2
This review discusses the recognition and management of
relapses in multiple sclerosis, and focuses on facts that are
applicable to the generalist, not specialist.
How is multiple sclerosis classified?
The clinical course of multiple sclerosis may vary.3 It is
relapsing-remitting from onset in 85% of cases, characterised
by episodes of neurological deficit (relapses) that recover (that
is, remit), to varying degrees; if relapses are severe and frequent
the term “rapidly evolving severe multiple sclerosis” is
sometimes used. In the other 15% of cases, a gradual progression
occurs from onset (primary progressive multiple sclerosis).
Relapsing-remitting multiple sclerosis converts to secondary
progressive multiple sclerosis after 15 years in 50% of cases.4
This conversion is gradual,5 with a decline in the number of
relapses6 7 and a steady deterioration in neurological function
between relapses.
Relapses were traditionally associated with relapsing-remitting
multiple sclerosis and secondary progressive multiple sclerosis.8
It has become increasingly recognised that various permutations
of relapses and progression occur within and between patients,
whatever their disease course. Hence a new classification system
was developed by consensus in 2013, which is yet to permeate
real life clinical practice fully. This system subclassifies
secondary progressivemultiple sclerosis and primary progressive
multiple sclerosis, based on activity (active versus non-active)
and progression (with progression versus without progression).
Activity is determined by relapses or activity on magnetic
resonance imaging, while progression is determined by sustained
accumulation of disability.5
Why is managing relapses important?
In recent years there has been a remarkable expansion in the
number of immunotherapies available for relapsing-remitting
multiple sclerosis, with a range of efficacies (fig 1⇓). Increasing
efficacy is, however, accompanied by an increased risk of
adverse events. Availability of potent treatments to suppress
disease activity has led to two major effects. Firstly, there is a
renewed importance of monitoring the occurrence of relapses
after starting first line treatment in case there is a need for
treatment escalation. Secondly, a zero tolerance approach to
relapses has become possible, leading to the concept of “no
evidence of disease activity” (NEDA).9 10 This has been adopted
as an outcomemeasure in clinical trials of multiple sclerosis,11 12
for the purpose of which NEDA is defined by the triad of no
evidence of relapse occurrence, no sustained progression of
disability, and no appearance of new lesions on magnetic
resonance imaging. Neurologists are currently divided on their
opinion regarding NEDA, and therefore the degree of tolerance
to ongoing inflammatory activity varies between centres and
countries.
Since the eligibility criteria for immunotherapy rely on
enumeration of relapses and their severity, the precise
recognition and documentation of relapses has gained additional
importance. In countries where such escalation is recommended
by national guidelines, a diagnosis of a relapse needs to be
followed by prompt communication of its occurrence to the
neurologist to enable a timely decision to be made regarding
initiation or escalation of immunotherapy.
A delay in treatment escalation may impact negatively on long
term outcome. However, evidence is conflicting. Some early
versus delayed treatment studies of established
relapsing-remitting multiple sclerosis suggest a lasting impact
on accumulation of disability (for example, interferon beta and
laquinimod),13 14 but not others.15 These studies were either
observational or extension trials, retrospectively looking for an
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The bottom line
• Relapse of multiple sclerosis is a patient reported, or objectively observed, event typical of an acute inflammatory demyelinating event
in the central nervous system, current or historical, with a duration of at least 24 hours
• The differential diagnosis of a relapse includes alternative neurological diagnoses, pseudo-relapses, short lived paroxysmal symptoms,
day to day fluctuations, and functional symptoms
• Clinically significant or severe relapses may benefit from treatment with corticosteroid for five days
• Documentation and timely communication of the relapse to the patient’s multiple sclerosis specialist service, such as through the
multiple sclerosis specialist nurse, is important, to enable timely decisions on immunotherapy initiation or escalation
• Non-adherence with immunotherapy is under-recognised by both patients and doctors
Sources and selection criteria
We carried out an electronic search through PubMed, Ovid, and CINAHL using the search terms “multiple sclerosis” and “relapse”. We also
searched personal reference archives and had discussions with colleagues. One author (CH) used information from three highly standardised
patient education programmes developed at the Hamburg centre.
early versus delayed start of treatment effect. A randomised
trial comparing immediate versus delayed start of treatment in
relapsing-remitting multiple sclerosis with long term disability
as the planned primary outcome has not been performed.
How common are relapses?
The true prevalence of relapses can be difficult to record since
patients present variably to community services, general
practices, and tertiary services, or do not contact health services
at all. Indeed a recent survey of patients with multiple sclerosis
showed that 28% of respondents failed to report their most
recent attack and 46% had failed to report an attack in the past.16
In England, with a prevalence for multiple sclerosis of 203 per
100 000 population,2 a relapsing-remitting multiple sclerosis
subtype prevalence of 47%,17 an average patient population of
6487 per practice,18 and a relapse rate of between 0.3 and 1.0,19
the average general practice would expect to see between two
and six relapses a year.
It is a recognised feature that the frequency of relapses decreases
with time from diagnosis and age, and relapse-free periods are
not uncommon.7 Annualised relapse rates in placebo groups of
randomised controlled trials have been decreasing with time20;
this is most likely the result of changes in trial populations in
response to the increasing availability of treatments, rather than
to a reflection of a changing clinical course of the disease.21
What factors affect the frequency of
relapses?
Several factors have been hypothesised to trigger relapses or to
influence the frequency of relapses, and their modifiable or
predictive nature makes them attractive candidates for
intervention. Substantial evidence to support an association with
relapses has been shown only for systemic infections, self
reported stress, and the postpartum period.22 Reasonable
experimental evidence shows that the association is causal in
the case of systemic infections.23 It might be worth taking steps
to prevent recurrent infections if they trigger relapses. Although
self reported stress may be a prodrome of relapses,24 external
threat increases the risk of relapse, suggesting a causal
association.25 Physical trauma,26 vaccinations,27 and epidural
analgesia28 are not associated with relapses. No controlled studies
have examined the effect of surgical operations. There is only
limited evidence that omega 6 fatty acid, exposure to sunlight,
and vitamin D reduce the relapse rate.22
How is a relapse diagnosed?
Diagnosis of a relapse is predominantly clinical. Since any part
of the central nervous system may be affected, the neurological
deficits are protean, and may involve one or multiple sites
(monofocal or multifocal, respectively). Common symptoms
include loss of visual acuity (optic neuritis), sensory alterations,
weakness, imbalance (ataxia), fatigue, and cognitive difficulty.
According to the 2010 revisions to the McDonald Criteria of
the International Panel on Diagnosis of Multiple Sclerosis,29 a
relapse “is defined as a patient-reported or objectively observed
event typical of an acute inflammatory demyelinating event in
the CNS [central nervous system], current or historical, with
duration of at least 24 hours, in the absence of fever or
infection.” A relapse typically develops over hours or days until
a plateau is reached, which may last days or weeks, followed
by complete or incomplete recovery at varying rates. Since
relapses may be multifocal and may have a fluctuating or
staggered onset and course, it may be difficult to differentiate
between a single complex relapse and multiple relapses close
to each other. Therefore a stable or improving period of 30 days
should separate the onset of subsequent events for them to be
distinguished as separate relapses.30 31
In the largest study of relapse phenotype to date, most relapses
were monofocal (74%) and the commonest relapse phenotype
was sensory (48%), followed by weakness (34%) and problems
with visual acuity (20%).32 Recurring relapses are more likely
to be of the same phenotype,32 33 but multiple relapses in the
same limb are uncommon,34 indicating that within individuals,
relapses may have a predilection for neuroanatomical area types
but not for precise location.
What are the differential diagnoses?
Since the diagnosis of relapses is predominantly clinical, it is
important to be aware of situations which may lead to
under-diagnosis or over-diagnosis of relapses (box 1). In
addition, several differential diagnoses need to be considered.
Alternative diagnoses
A diagnosis of multiple sclerosis does not render a patient
immune from a second neurological condition. This can include
common (for example, compressive spondyloradiculopathy,
carpal tunnel syndrome) or uncommon (for example, cauda
equina syndrome, cerebral sinus thrombosis) diagnoses.
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Box 1 Symptoms or situations leading to under-diagnosis or over-diagnosis of relapses
Non-physical relapses
Characterised by purely subjective symptoms such as increased fatigue, or cognitive impairment, with no physical component
Minor relapses
Where it is difficult to measure symptoms objectively such as sensory disturbances, or clinically undetectable visual or other symptoms
Infection related relapse
May be dismissed owing to the occurrence of infection, or misdiagnosed as pseudo-relapses. It is a well known observation that systemic
infections are associated with an increased likelihood of relapses during the “at risk period,” which extends from one week before to five
weeks after the onset of the infection; infection associated relapses account for one third of all relapses.w12-w17 It has been shown that
infection related relapses are accompanied by true inflammatory activity, with gadolinium enhancementw14
Relapses masquerading as progression and vice versa
Multiple overlapping relapses with poor recovery may masquerade as progression; conversely progression may masquerade as multiple
reported relapses, especially with poor historians or cognitive problems. Multiple collateral histories are important if relapses are unusually
high in number with disproportionately little accumulation of disability, or if a diagnosis of secondary progression is being considered
early after onset of multiple sclerosis (conversion to secondary progression only occurs in 25% at six years after onset)w18
Relapses consisting of a cluster of paroxysmal symptoms
Although single paroxysmal episodes do not constitute a relapse, multiple episodes occurring within a self limited period with a duration
longer than 24 hours constitute a relapsew19
Paroxysmal symptoms
Patients with multiple sclerosis are prone to paroxysmal
symptoms, such as trigeminal neuralgia, Lhermitte’s
phenomenon, and tonic spasms. These are usually intermittent
and are not relapses if present for less than 24 hours.30
Pseudo-relapses
A pseudo-relapse is an exacerbation of previous symptoms
occurring in the context of elevation of body temperature (heat,
exercise, or fever) or systemic inflammatory activity (infection
or another ongoing systemic illness), which cause conduction
block in abnormal axons.3 Hence unlike relapses,
pseudo-relapses are always exacerbations of previous symptoms,
are typically transient, and their onset and resolution roughly
coincide with the triggering situation.
Day to day fluctuations
Day to day fluctuations in chronic symptoms are common in
multiple sclerosis35 and may be misinterpreted as relapses. This
is usually indicated by their stereotypical nature, and a
disproportionate frequency of reported relapses, higher than
expected when considering the patient’s disability progression.
Functional relapses
Medically unexplained symptoms are common, especially in
general practice, where they can constitute two thirds of all
reported symptoms36 and account for the predominant confident
diagnosis in 4% of consultations.37 Their occurrence in the
context of multiple sclerosis can be challenging. Non-organic
“relapses” are well documented, and functional overlay during
genuine relapses may inflate severity.38-41 It is important to
recognise the unconscious needs underlying this presentation.
Where are relapses best managed?
Uncommonly there is a need for hospital admission, owing to
the severity of relapse (such as severe paralysis, swallowing or
breathing difficulty, urinary retention), the need for intensive
physiotherapy, or doubts about diagnosis. Most relapses can be
managed without hospital admission, with support from
community based multiple sclerosis nurses and
neurorehabilitation services or multiple sclerosis relapse clinics,
or both. Communication of relapse occurrence to the multiple
sclerosis specialist team is essential, and therefore
documentation of relapse is important (box 2). Severity of
relapses may importantly affect decisions about immunotherapy
in some healthcare systems and are important to document.
NHS England has produced some guidelines to help in the
assessment of severity (fig 2⇓).31 These are not validated and
each case should be treated on its ownmerits, within the context
of the individual patient.
How are relapses treated?
Use of high dose short term corticosteroids is the accepted
treatment for relapses.42 Before corticosteroid is administered,
a rapid infection screen (symptoms, temperature, urine dipstick)
is recommended, since infections commonly associate with
relapses (box 1). Active symptomatic infections need treatment
before corticosteroids are given. Relapses accompanied by an
asymptomatic dipstick positive urinary tract infection can be
safely, simultaneously, and rapidly treated with corticosteroids
and trimethoprim until the results of microbiological culture
and sensitivity analysis become available.43
Three systematic reviews, the largest of which was a
meta-analysis of 12 randomised controlled trials in 1714 people,
showed that corticosteroid treatment shortened the duration of
relapses but did not seem to affect long term outcome.44-46
Improvement was seen in trials allowing randomisation up to
eight weeks after the onset of relapse.45 There is considerable
diversity among neurologists and national guidelines regarding
dose, duration, and choice of corticosteroid agent.47TheNational
Institute for Health and Care Excellence (NICE) recommends
oral treatment with 500 mg methylprednisolone daily for five
days.42 If patients are in hospital, or if oral corticosteroids are
not effective, intravenous treatment with 1 gmethylprednisolone
daily for 3-5 days is recommended.42 Oral treatment is as
effective as the intravenous route.48 The clinical effectiveness
of corticosteroid administered in home or outpatient settings is
similar.49
The decision to treat is best taken in conjunction with the patient
in a process of shared decision making,50 based on the provision
of adequate information and an assessment of the impact of the
relapse on the patient. In a randomised controlled trial, patients
educated about the evidence on corticosteroid use during relapse
decided to treat fewer relapses, opted for more oral than
intravenous corticosteroids, had higher levels of perceived
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Box 2 Important characteristics of a relapse to document
• Date of onset
• Duration
• Functional system affected
• Severity (mild, moderate, or severe)
• Any treatment given for the relapse
• Extent of recovery
• Length of immunotherapy and adherence
autonomy, and had less contact with their clinicians.51 Patients
were able to self administer oral treatments with no substantial
risks; however, NICE guidelines advise against giving patients
a supply of corticosteroids to self administer for future relapses.42
Clinical study data supporting a second ultra high (2 g/day)
corticosteroid treatment after failure of a first course are missing,
and this practice is still based on animal data.52 In tertiary
settings, plasmapheresis is used for severe corticosteroid
resistant relapses, based on one small randomised controlled
trial.53 Two well conducted randomised controlled trials of 76
and 19 patients showed that intravenous immunoglobulins as
add-on treatment with methylprednisolone did not confer
additional benefit.54 55 It has been suggested that intravenous
immunoglobulins may be a therapeutic option if steroids are
contraindicated, based on one small study of 17 patients.56
Advising on recovery and prognosis after
relapse
It is important to manage expectations during a relapse,
especially early after a diagnosis of multiple sclerosis.
Recovery from individual relapse
Significant recovery usually occurs within the first two or three
months,57 58 but relapses may continue to improve for up to 12
months.57 Residual disability is seen in one third to half of all
relapses59-62 and is more likely if the relapse is severe, multifocal,
initially slow to recover, and in people 30 years or older.60 62
One study indicates that a lack of recovery from a relapse
predicts incomplete remission of future relapses.63
Impact of relapses on long term disability
Whether relapses affect long term disability is a contentious
issue. Modern evaluation of long term follow-up patient cohort
studies suggests that overall relapse rate does not impact on
long term disability (several studies, recently reviewed),64 and
although relapses in the first two years seem to be important,6 65
the effect of individual relapses is overshadowed by the onset
of progressive disease beyond this initial period.66 Hence,
currently it is generally accepted that the greatest determinant
of irreversible neurological disability is entry into the
progressive phase.
Rehabilitation
A recent systematic review has tackled rehabilitation
interventions in relapses.67 Three studies were identified; two
used a before and after design, whereas one small study (n=40)
applied a randomised design. All studies usedmultidisciplinary
interventions and showed strong improvements. The specificity
of the effect through control of the amount of attention is,
however, unclear. Owing to this and other methodological
problems, the added value of a comprehensive rehabilitation
intervention needs further investigation.
The role of the multiple sclerosis
specialist nurse
Although their role varies between countries and regions,68
multiple sclerosis nurses have become integral to the care of
the patients in relapse. Perhaps, most importantly, the nurses
provide a vital link between general practices, community health
services, social support, and neurology specialist care. When
relapse occurs these nurses are typically the patient’s first port
of call through, for instance, a dedicated telephone helpline.
Increasingly they provide a rapid (for example, within 48 hours),
responsive, reliable service, which may be inclusive of modern
methods of communication such as text messaging or video and
voice over internet (VoIP). Multiple sclerosis nurses can help
general practitioners in the diagnosis of a relapse, particularly
whenmeticulous history takingmay be needed. They can screen
for infection, prescribe steroids if needed, and provide support
during the relapse, including the identification of specific needs
and referral to the appropriate allied health professionals. In
most centres, multiple sclerosis nurses follow up patients at six
weeks post-relapse to assess recovery, provide relapse education,
deal with any issues with adherence or side effects from
immunotherapies, and communicate with the patient’s
neurologist.
Although high quality research into the cost effectiveness of
multiple sclerosis nurses is lacking, and it is now hard to justify
the ethics of controlled studies since they have become so
essential, there is evidence supporting their role. Multiple
sclerosis nurses facilitate a timely response to relapses; in one
study69 patients reported their relapse symptoms to a nurse
sooner (within 10 days of onset) compared with a mean time
of 51 days when reporting the same symptoms to a general
practitioner; 85% of patients were treated for their relapse within
10 days of first reporting symptoms; and a threefold increase
in treatment capacity occurred. In a more recent study, a
noticeable reduction in hospital bed utilisation by patients with
multiple sclerosis was seen.70
Relapse occurrence: implications for
immunotherapy
Relapses may be a reflection of non-adherence or may signal
the need for initiation of immunotherapy or its escalation, if
there has been a suboptimal response to immunotherapy.
Adherence
Treatment adherence may be assessed and managed at
community level, by the general practitioner or multiple sclerosis
specialist nurse. Non-adherence to drugs may be an underlying
reason for relapse and is under-recognised by doctors.71 Its
management may avoid unnecessary referral to neurology and
treatment changes. Non-adherence may manifest as
discontinuation or incomplete persistence.
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Discontinuation—In the literature, mean discontinuation rates
of first line injectable treatments range from 10% to 50%,72-74
with major reasons including adverse events and perceived lack
of efficacy. Common adverse events include flu-like symptoms
with interferon beta, injection site reactions with glatiramer
acetate, and flushing or gastrointestinal symptomswith dimethyl
fumarate. Discontinuation usually necessitates switching to
another agent.
Incomplete persistence, or “treatment breaks”—These are also
prevalent. Two studies using electronic means of monitoring
injections found that 9% to 20% of patients were administering
less than 80% of injections, with a mean adherence of 66%.75 76
In addition, patients underestimated their adherence.75Collateral
history taking and electronic or manual (for example, diary)
monitoring may help in the diagnosis of incomplete persistence.
Causes of incomplete persistence are numerous. If forgetfulness
is the main culprit, simple measures may include reminder
alarms, pill boxes, smartphone apps (recently reviewed),77 and
the help of relatives. If side effects are the main reason,
prophylactic drugs (for example, non-steroidal anti-inflammatory
agents before injection), practical measures such as
administering weekly injections on a Saturday, or switching to
an alternative injectionmethodmay be enough. Adequate patient
education,78 software based telephone contact,79 nursing
support,80 and treatment of depression81 may help.
Immunotherapy initiation or escalation
Review of immunotherapy falls within the remit of specialist
neurology services; hence discussion or referral, or both is
recommended. Occurrence of a relapse in a treatment naive
patient may render them eligible for first line immunotherapy
(fig 1 and box 3).
For patients recently established on first line treatment, most
neurologists would wait at least six months or a year before
offering treatment escalation, unless a rapidly evolving severe
clinical course becomes apparent. It is important to be aware of
the potential for overzealous escalation of treatment at low levels
of disability in the context of over-interpretation of relapses.
Only two phase III treatment escalation trials have been
performed: natalizumab add-on to interferon beta82 (findings
did not enter clinical practice owing to high risk of progressive
multifocal leucoencephalopathy) and alemtuzumab in patients
non-responsive to interferon beta or glatiramer acetate.83 Several
small other treatment escalation studies exist.84Hence guidelines
and decisions on escalation to other treatments are mainly based
on data from comparator studies that have not been powered to
detect superiority (for example, DEFINE),85 post hoc subgroup
analysis comparing treatment naive with non-naive patients in
placebo controlled trials (for example, FREEDOMS,86
TRANSFORMS),87 and less appropriately from comparing
relative risk reductions across different placebo controlled
studies. Clearly, large well designed treatment escalation or
comparator studies are needed. This lack of evidence is partly
responsible for variation in choice of second line treatment, but
other factors include neurologist and patient preference, local
practice, regional or national guidelines, availability, and disease
severity.
The decision to start or escalate immunotherapy, and the choice
of agent, is best made using shared decision making, tailored
to individual patients, which takes into account patient factors
(autonomy and preference) and physician factors (medical
evidence and expertise).88 Patients with multiple sclerosis are
able to process evidence and scientific uncertainty without
additional emotional burden, and they can be educated in very
basic statistics such as calculations of absolute risk reduction
as presented in figure 1.89
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Box 3 Immunotherapy for relapsing-remitting multiple sclerosis
First line treatment
• Interferon betaw20
• Glatiramer acetatew20
• Teriflunomidew21
• Dimethyl fumaratew22
• Alemtuzumabw23
First line, rapidly evolving severe relapsing remitting multiple sclerosis
• Natalizumabw20
Second line treatment
• Fingolimodw20
• Natalizumabw20
Questions for future research
What is the value of treating to a target of “no evidence of disease activity”?
What is the relative benefit of immunotherapies when compared head to head?
What is the benefit of starting immunotherapy early in delayed start drug trials?
What is the benefit of treatment escalation using specific immunotherapies?
Which multiple sclerosis specialist nursing roles are cost effective during management of relapses?
Which forms of rehabilitation are cost effective after a multiple sclerosis relapse?
Would better information provision and shared decision making pathways increase patient participation and psychological wellbeing?
Additional educational resources
Resources for healthcare professionals
NICE guidelines for management of multiple sclerosis in primary and secondary care (www.nice.org.uk/guidance/cg186)
NHS England commissioning policy for immunotherapies (www.england.nhs.uk/wp-content/uploads/2013/10/d04-p-b.pdf)
Resources for multiple sclerosis specialist nurses (www.msnursepro.org/)
Resources for patients
Multiple sclerosis societies (www.mssociety.org.uk/, www.mstrust.org.uk/, and www.nationalmssociety.org/)
Patient decision aids (http://sdm.rightcare.nhs.uk/pda/multiple-sclerosis/ and www.msdecisions.org.uk/)
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Figures
Fig 1 Three possible outcomes in patients with multiple sclerosis within two years of trial duration. For patient education
purposes, the absolute risk reduction (ARR) is recommended versus the relative risk reduction (RRR), since the ARR more
closely reflects real treatment effects. The RRR is the ARR expressed as a percentage of relapsing patients in the control
group. Therefore the RRR always appears larger than the ARR. Each bar represents the outcome of 100 patients, and
numbers are therefore equivalent to percentages
Fig 2 Assessing severity of relapses. “Severe” and “disabling” are used interchangeably, as are “moderate” and “clinically
significant”
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